Reimbursement Past Sema denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for reimbursement past sema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Past Semaglutide Claims as Duplicate Therapy

Aetna's "duplicate therapy" denial for a past semaglutide claim typically arises when the plan's records show that the patient was concurrently covered under another GLP-1 receptor agonist benefit, a concurrent diabetes or obesity medication claim was on file for the same period, or the reimbursement request overlaps with a claim already processed under a different benefit category (e.g., pharmacy vs. medical benefit). The plan's position is that it should not pay twice for what it considers equivalent therapeutic coverage. This denial reason is especially common for semaglutide because the drug appears under multiple brand names and at least two distinct FDA indications (type 2 diabetes and chronic weight management), which can cause the plan's duplicate-detection logic to misfire.

## Why It Is Appealable

A duplicate-therapy determination is a factual and administrative claim, not a clinical judgment — which makes it one of the more straightforward denials to overturn. If the prior claim was for a different indication, a different brand, a different route of administration, or a different plan benefit category, it is not a duplicate by definition. Errors in the plan's duplicate-detection logic are directly correctable on internal appeal.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. The appeal should be primarily documentary — demonstrate that the flagged "duplicate" claim differs in indication, product, or benefit category from the current claim.
• External review (ACA §2719): Available after internal exhaustion, within approximately four months of final denial. Binding on Aetna.
• ERISA §503: Full-and-fair review rights apply to self-funded employer plans.

## Documentation to Gather

1. EOB for both the denied claim and the alleged duplicate — obtain both explanation-of-benefits documents and compare them side by side: dates of service, NDC or HCPCS codes, diagnosis codes, and benefit categories. 2. Pharmacy dispensing records — confirming what was dispensed, when, and under which benefit. 3. Prescriber documentation — confirming the specific indication for which semaglutide was prescribed, to establish it is distinct from any other concurrent claim. 4. Coordination of benefits records (if applicable) — if a second insurer is involved, document the primary/secondary payment sequence. 5. Letter of explanation from the prescriber — confirming that no therapeutically equivalent agent was dispensed concurrently for the same indication.

## Criteria-Mapping Structure

Present a side-by-side comparison table: the denied claim on the left (date, product, indication, benefit category), the alleged duplicate on the right. Highlight every column where the two claims differ. Attach EOBs and dispensing records as exhibits. This format directly disproves the "duplicate" classification without requiring any clinical argument.